Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts
Title
Grant Type
Focus Area
Country
Application Due Date
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Enhancing awareness and well understanding of the management in hypothalamic pituitary dysfunction, growth disorders
Release Date:
Review Process: Pfizer Internal
Education Rare Disease Japan
Long-acting Growth Hormone Research
Release Date:
Review Process: Pfizer Internal
Research Rare Disease All
COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer Grant Support Program (United States and Europe)
Release Date:
Review Process: Pfizer Internal
Quality Improvement Oncology All
2020 Osteoarthritis and Osteoarthritis Pain- Virtual Learning
Release Date:
Partner:

Lilly

Review Process: Pfizer Internal
Education Internal Medicine All
NASH – Future of Non-invasive Diagnosis Technologies
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine All
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator
Release Date:
Review Process: Pfizer Internal
Quality Improvement Rare Disease USA
Pfizer-ISID 2020 AFME Grant Challenge (Africa and the Middle East)
Release Date:
Partner:

International Society for Infectious Diseases (ISID)

Review Process: Expert Review Panel
Quality Improvement Hospital All
Advances in Oncology Therapy in Renal Cell Carcinoma
Release Date:
Review Process: Pfizer Internal
Education Oncology Japan
Increasing Awareness of Nuclear Scintigraphy in Cardiac Amyloidosis
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Pfizer and RCNi – Providing Access to Learning Resources for Nurses in the APAC/China Region
Release Date:
Partner:

RCNi (subsidiary of the Royal College of Nursing)

Review Process: Pfizer Internal
Education Internal Medicine Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Taiwan, Thailand, Vietnam
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Latin America
Release Date:
Review Process: Pfizer Internal
Research Rare Disease Argentina, Brazil, Chile, Colombia
Vaccine Preventable Diseases – COVID-19 (closed early)
Release Date:
Review Process: Pfizer Internal
Research Vaccines All